IDEAYA Biosciences Inc
IDYA32.170USD
+0.400+1.26%
終値 02/06, 16:00（ET）15分遅れの株価
2.82B時価総額
損失額直近12ヶ月PER
詳細情報 IDEAYA Biosciences Inc 企業名
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
IDEAYA Biosciences Incの企業情報
企業コードIDYA
会社名IDEAYA Biosciences Inc
上場日May 23, 2019
最高経営責任者「CEO」Hata (Yujiro S)
従業員数131
証券種類Ordinary Share
決算期末May 23
本社所在地7000 Shoreline Ct, Suite 350
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94080
電話番号16504436209
ウェブサイトhttps://www.ideayabio.com/
企業コードIDYA
上場日May 23, 2019
最高経営責任者「CEO」Hata (Yujiro S)
IDEAYA Biosciences Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
事業別USD
会社名
収益
比率
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
地域別USD
会社名
収益
比率
United States
7.00M
100.00%
事業別
地域別
事業別USD
会社名
収益
比率
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
株主
更新時刻: Sat, Feb 7
更新時刻: Sat, Feb 7
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
他の
57.27%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
他の
57.27%
種類
株主統計
比率
Investment Advisor
49.41%
Investment Advisor/Hedge Fund
32.26%
Hedge Fund
19.91%
Research Firm
3.93%
Venture Capital
3.62%
Pension Fund
0.95%
Individual Investor
0.91%
Bank and Trust
0.45%
Insurance Company
0.07%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
489
96.76M
110.37%
-16.87M
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
13.15M
15%
+9.25K
+0.07%
Sep 30, 2025
Capital Research Global Investors
6.55M
7.47%
--
--
Sep 30, 2025
Janus Henderson Investors
6.43M
7.33%
+222.10K
+3.58%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.34M
7.23%
-336.88K
-5.05%
Sep 30, 2025
The Vanguard Group, Inc.
4.90M
5.59%
-19.74K
-0.40%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-1.42K
-0.03%
Sep 30, 2025
Point72 Asset Management, L.P.
3.82M
4.35%
-1.21M
-24.12%
Sep 30, 2025
Baker Bros. Advisors LP
3.28M
3.74%
+1.16M
+54.59%
Sep 30, 2025
State Street Investment Management (US)
3.24M
3.7%
-144.86K
-4.28%
Sep 30, 2025
Adage Capital Management, L.P.
2.90M
3.31%
+1.66M
+134.24%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
詳細を見る
Tema Oncology ETF
比率3.49%
ALPS Medical Breakthroughs ETF
比率1.16%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.83%
State Street SPDR S&P Biotech ETF
比率0.72%
First Trust Innovation Leaders ETF
比率0.7%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.45%
ProShares Ultra Nasdaq Biotechnology
比率0.38%
Avantis US Small Cap Equity ETF
比率0.29%
Invesco Nasdaq Biotechnology ETF
比率0.27%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
